Full-Time

Oncology Pathology Assistant

PA, Ascp, Or CT, Ascp

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Biotechnology
Healthcare

Senior

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Genomics
Biology Lab & Research
Biology & Biotech

You match the following Natera's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree, or higher, with certification as a Pathologists' Assistant or Cytotechnologist by the American Society of Clinical Pathology (ASCP), or equivalent board, is required.
  • Minimum of 5 years of experience in anatomic pathology including extensive knowledge of solid tumor pathology.
Responsibilities
  • Assist the medical and customer service teams with the interpretation of oncology pathology reports to identify optimal samples to request when initial FFPE blocks or slides are inadequate for testing.
  • Read and ensure accurate curation of clinical history, diagnosis, progress notes, and specimen information is entered into the Signatera sample database.
  • Assist with devising strategies to stratify data for retrieval from the Signatera sample database and other databases as necessary.
  • Maintain proficiency with and help organize diagnostic data according to pertinent WHO guidelines.
  • Serve as subject matter expert to the Laboratory Director, Genetic Counseling, Customer Experience, Sales, and Clinical Trial teams for pathology reports.
  • Assist in the identification and alert the Laboratory Director when samples may have been collected at suboptimal timepoints and/or fixative conditions.
  • Assist Genetic Counseling and Customer Experience teams in identification and procurement of optimal additional samples, as necessary.
  • Provide professional support for the Clinical Trial team through accurate and organized data transfer.
  • Performs other duties as assigned.
Desired Qualifications
  • Ability to accurately understand and convey information found in anatomic pathology reports to team members for a wide variety of solid tumors, including but not limited to lung, colon, and breast cancer.
  • Ability to identify potential diagnostic sample(s) that will ensure successful testing.
  • Ability to communicate effectively with team members and referring pathology laboratories.
  • Ability to build relationships with referring pathology laboratories.
  • Detail oriented. Ability to think broadly about the importance of clinical information and to work independently.

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and organ health assessment. Their products include the Signatera test for cancer patients and the Panorama NIPT for prenatal screening, with a strong emphasis on personalized genetic counseling. Natera stands out by providing specialized testing services directly to healthcare providers and patients, ensuring early detection of health issues. The company's goal is to improve patient care through advanced genetic testing solutions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • Growing personalized medicine trend enhances need for Natera's customized genetic tests.
  • Expansion of telehealth services aligns with Natera's remote genetic counseling offerings.

What critics are saying

  • Allegations of deceptive practices could harm Natera's reputation and lead to legal issues.
  • New Prospera Heart features may face adoption challenges without independent validation.
  • Ongoing legal investigations could result in financial penalties affecting Natera's stability.

What makes Natera unique

  • Natera's Signatera test offers significant lead time in detecting cancer recurrence.
  • Prospera Heart test integrates Donor Quantity Score for enhanced transplant rejection detection.
  • Panorama NIPT uniquely determines fetal RhD status, aiding in prenatal care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

10%
BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.

Yahoo Finance
Jun 17th, 2024
Natera Launches Differentiated New Feature For Prospera(Tm) Heart Test, Enhancing Detection Of Rejection For Transplant Patients

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejectionAUSTIN, Texas, June 17, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.Traditionally, donor-derived cell-free DNA (dd-cfDNA) tests have reported rejection risk based only on the fraction of dd-cfDNA in the blood vs. the total cfDNA (dd-cfDNA %). This fraction can be confounded by fluctuations in the amount of background total cfDNA (the denominator), which are sometimes caused by factors unrelated to the health of the transplant, including infection, surgery, or chemotherapy.Prospera Heart now incorporates a second metric – the DQS – that normalizes for the background total cfDNA. Prospera Heart with DQS combines the traditional donor fraction and the new DQS into a two-threshold algorithm, delivering a single result with more accurate risk assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR)."Over the last two decades, Natera has pioneered cfDNA testing across women’s health, oncology, and transplant medicine," said Michael Olymbios, M.D., Medical Director, Heart Transplant. "Our extensive experience with cfDNA and Natera’s culture of continuous innovation drove us to further refine Prospera Heart by introducing this two-threshold algorithm to better serve the transplant community."A study performed at the University of Utah and the University of California San Diego showed that incorporating DQS enhanced the performance of Prospera Heart in screening for biopsy-proven active rejection